REUTERS - Strides Arcolab Ltd said on Wednesday it had received the U.S. Food and Drug Administration's approval for a plant in Italy, helping it foray into the semi-solid market in the United States.
Strides expects its first semi-solid product to be commercialised by the first quarter of next year, it said in a statement. The product will be marketed by one of the top 10 generic companies in the U.S. market.
It did not name the company.
The Strides facility in Milan makes liquids, semi-solids, ointments and creams.
(Reporting by Devidutta Tripathy in New Delhi; Editing by Prateek Chatterjee)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app